Infliximab therapy in pediatric patients 7 years of age and younger

Journal of Pediatric Gastroenterology and Nutrition

Volumn 59, Issue 6, 2014, Pages 758-762

  Kelsen, Judith R ^a   Grossman, Andrew B ^a   Pauly Hubbard, Helen ^a   Gupta, Kernika ^a   Baldassano, Robert N ^a   Mamula, Petar ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Infliximab; Maintenance of therapy; Response rate

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ANAPHYLAXIS; ARTICLE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; COUGHING; CROHN DISEASE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY BOWEL DISEASE; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OXYGEN DESATURATION; PHENOTYPE; RETROSPECTIVE STUDY; TREATMENT DURATION; ULCERATIVE COLITIS; COLITIS; COLITIS, ULCERATIVE; INFLAMMATORY BOWEL DISEASES; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; COLITIS; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84916600684     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000533     Document Type: Article

References (25)

1. Khera TK, Dick AD, Nicholson LB. Mechanisms of TNFalpha regulation in uveitis: focus on RNA-binding proteins. Prog Retin Eye Res 2010;29:610-21.
2. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685-98.
3. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
5. Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012;18:201-11.
6. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
7. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9.
8. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73.
9. Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009;15:816-22.
10. Muise AM, Snapper SB, Kugathasan S. The age of gene discovery in very early onset inflammatory bowel disease. Gastroenterology 2012;143:285-8.
11. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833-8.
12. Lamireau T, Cezard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2004;10:745-50.
13. Mamula P, Markowitz JE, Cohen LJ, et al. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr 2004;38:298-301.
14. Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005;41:416-21.
15. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47.
16. CrandallW, Hyams J, Kugathasan S, et al. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr 2009;49:183-90.
17. Rosh JR, Lerer T, Markowitz J, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009;104:3042-9.
18. Crombe V, Salleron J, Savoye G, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis 2011;17:2144-52.
19. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501-8.
20. Steenholdt C, Svenson M, Bendtzen K, et al. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34:51-8.
21. Steenholdt C, Svenson M, Bendtzen K, et al. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. J Crohns Colitis 2012;6:108-11.
22. de Ridder L, Weersma RK, Dijkstra G, et al. Genetic susceptibility has a more important role in pediatric-onset Crohn's disease than in adultonset Crohn's disease. Inflamm Bowel Dis 2007;13:1083-92.
23. Biank V, Broeckel U, Kugathasan S. Pediatric inflammatory bowel disease: clinical and molecular genetics. Inflamm Bowel Dis 2007; 13:1430-8.
24. Glocker EO, Frede N, Perro M, et al. Infant colitis - it's in the genes. Lancet 2010;376:1272.
25. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009;361:2033-45.